Figure 2.
Diagram of triplet regimens. Triplet treatment regimens are represented by the bars. Continuously dosed oral drugs are depicted by a solid line and infusion therapies as bars. Regimens that used an MRD or response-guided approach to determine if treatment was discontinued have a translucent bar to indicate that some patients continued treatment. Treatments that are continued indefinitely with no set timepoint to end have an arrow at the right side. All treatment regimens are diagramed to scale with respect to each, with the length of the bar showing time on each drug. The ibrutinib, venetoclax, and obinutuzumab (IVO) diagrams are based on multiple studies: a phase 2 study; the CLL2-GIVe and GAIA/CLL13 studies, which used the same treatment; and AO41702.19,26,28 The AVO and ZVO diagrams are based on the phase 2 studies with these regimens.29,30

Diagram of triplet regimens. Triplet treatment regimens are represented by the bars. Continuously dosed oral drugs are depicted by a solid line and infusion therapies as bars. Regimens that used an MRD or response-guided approach to determine if treatment was discontinued have a translucent bar to indicate that some patients continued treatment. Treatments that are continued indefinitely with no set timepoint to end have an arrow at the right side. All treatment regimens are diagramed to scale with respect to each, with the length of the bar showing time on each drug. The ibrutinib, venetoclax, and obinutuzumab (IVO) diagrams are based on multiple studies: a phase 2 study; the CLL2-GIVe and GAIA/CLL13 studies, which used the same treatment; and AO41702.19,26,28 The AVO and ZVO diagrams are based on the phase 2 studies with these regimens.29,30 

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal